02/03/2022at 07:44

Abbvie takes over Novo Holdings portfolio company

Syndesi Therapeutics has been acquired by Abbvie in a USD 1bn deal.

by victor emil kristensen, translated by catherine brett

After four years of ownership, Novo Holdings has decided to sell Belgian portfolio company Syndesi Therapeutics to Abbvie.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Finnish investor looks for Nordic investors in its new life science & health fund
For subscribers
Novo Holdings acquisition highlights growing pharma commercialization service market, says managing partner
For subscribers
Biotech boss overjoyed by new life science fund: "The more the merrier"
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Front page now

Per Wold-Olsen officially stepped down as GN's chair at the company's AGM | Photo: Mik Eskestad

Hearing health

Former GN chair says there have been no acquisition signs from Demant owner

Per Wold-Olsen left the chairperson position two weeks ago after 15 years – he now reveals there haven’t been acquisition talks behind closed doors during his time at the company.

For subscribers

Regulation

CHMP recommends nine drugs in March

For subscribers

Nicolai Buhl, executive vice president for innovation at Coloplast, is busy winning a clinical contest against a catheter competitor | Foto: Mik Eskestad

Medtech

Coloplast challenges its biggest catheter competitor in clinical contest

For subscribers

Other

Top news from MedWatch this week

Pharma & biotech

Former Bavarian Nordic chairman sees opportunities in Johnson & Johnson's RSV exit

For subscribers

Pharma & biotech

Novo Nordisk helps Canada resolve Ozempic issue

For subscribers

Novo Nordisk helps Canada resolve Ozempic issue

Americans were reportedly crossing the border seeking the diabetes drug with a strong weight-loss effect until barred from purchases.

For subscribers

Minister for the Interior and Health of Denmark Sophie Løhde must answer questions concerning Novo Nordisk's funding of a Danish patient group | Foto: Ida Marie Odgaard

Pharma & biotech

Danish health minister to answer questions about Novo Nordisk sponsorship of patient group

The Danish minister for health has six business days to answer questions posed by a parliamentarian.

For subscribers

Hearing health

Former GN chair says there have been no acquisition signs from Demant owner

Per Wold-Olsen left the chairperson position two weeks ago after 15 years – he now reveals there haven’t been acquisition talks behind closed doors during his time at the company.

For subscribers